Hightower Clinical | Oklahoma City, OK
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This Phase III, randomized, two-arm, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus Phesgo compared with Phesgo after induction therapy with Phesgo plus taxane in participants with human epidermal growth factor receptor 2 (HER2)-positive, estrogen receptor (ER)-positive advanced breast cancer (metastatic or locally advanced disease not amenable to curative treatment) who have not previously received a systemic non-hormonal anti-cancer therapy in the advanced setting.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Maintenance Phase Inclusion Criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
812 participants in 3 patient groups
Loading...
Central trial contact
Reference Study ID Number: WO43571 https://forpatients.roche.com/
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal